You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 復星醫藥港A齊升 港股急升近6% 復星CAR-T申報上市獲受理
格隆匯 02-25 10:15
格隆匯2月25日丨復星醫藥港A齊升,A股放量漲超5%,港股升5.77%,報22.9港元,暫成交6526萬港元,最新總市值586.9億港元,復星CAR-T申報上市!用於治療成人復發或難治性大B細胞淋巴瘤。復星醫藥總裁兼CEO吳以芳表示,“FKC876是復星凱特在中國推進商業化的第一個CAR-T細胞治療產品,也是國家藥品監督管理局迄今為止正式受理上市申請的第一個CAR-T細胞治療產品。此次新藥上市申請的受理更為我們推動世界領先的細胞治療產品在中國的成功落地和自主創新增加了信心。本次申請上市的是從美國Kite Pharma 引進的產品,已獲得FDA的批准,所以預計大概率能夠獲得通過。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account